Premium
Heterogeneity of α 2 ‐adrenoceptors in rat cortex but not human platelets can be defined by 8‐OH‐DPAT, RU 24969 and methysergide
Author(s) -
Brown C.M.,
MacKin A.C.,
McGrath J.C.,
Spedding M.,
Kilpatrick A.T.
Publication year - 1990
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1990.tb12954.x
Subject(s) - yohimbine , rauwolscine , chemistry , idazoxan , methysergide , oxymetazoline , binding site , endocrinology , medicine , population , agonist , receptor , prazosin , antagonist , biology , biochemistry , environmental health
1 Saturation experiments indicated that [ 3 H]‐yohimbine binding was specific, saturable and labelled a single population of sites in rat cerebral cortex ( K d 5.3 ± 0.9 n m , B max 121 ± 10 fmol mg −1 protein) and human platelets ( K d 0.7 ± 0.1 n m , B max 152 ± 10 fmol mg −1 protein). 2 The α 2 ‐adrenoceptor antagonists, yohimbine, rauwolscine, WY 26703, idazoxan and BDF 6143 displaced [ 3 H]‐yohimbine binding to each tissue in a simple manner, with high affinity and Hill slopes close to unity. 3 The α 1 ‐adrenoceptor agonist, oxymetazoline and the antagonist prazosin inhibited the binding of [ 3 H]‐yohimbine to rat cortex in a complex manner consistent with an interaction at more than one site. However, indoramin and WB 4101 only appeared to interact with one site. In contrast, in human platelets, all antagonists gave rise to monophasic displacement curves with Hill slopes close to unity suggesting a single site of interaction. 4 The 5‐hydroxytryptamine (5‐HT) receptor ligands, 8‐hydroxy‐2‐(di‐n‐propylamino)‐tetralin (8‐OH‐DPAT), RU 24969, and methysergide inhibited the binding of [ 3 H]‐yohimbine to rat cortex with high and low affinity, consistent with an interaction with two populations of binding sites. However, inhibition of [ 3 H]‐yohimbine binding to human platelets suggested a single site of interaction. The low affinity of 5‐HT, 5‐carboxyamidotryptamine (5‐CT) and dipropyl‐5‐CT indicated that [ 3 H]‐yohimbine was not labelling a 5‐HT 1 ‐like site in rat cortex. 5 The ability of 8‐OH‐DPAT, RU 24969 and methysergide in addition to prazosin and oxymetazoline to differentiate [ 3 H]‐yohimbine binding provides additional pharmacological evidence for heterogeneity within rat cortical α 2 ‐adrenoceptors. However, if the two sites in rat cortex that are differentiated by the 5‐HT ligands represent α 2A ‐ and α 2B ‐adrenoceptor subtypes as defined by prazosin and oxymetazoline, then they do not correspond to the population of sites in human platelets. As receptor classification should be linked to affinity of drugs rather than tissue distribution, the current classification of α 2 ‐adrenoceptor subtypes does not appear to be satisfactory.